Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

BACKGROUND: The effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) by age group (< 65, 65–74, and ≥ 75 years) are uncertain. We examined retention rates reflecting the effectiveness and safety of bDMARDs in actual clinical practice for clarifying optimal therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawabe, Akio, Nakano, Kazuhisa, Kubo, Satoshi, Asakawa, Takeshi, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282084/
https://www.ncbi.nlm.nih.gov/pubmed/32513309
http://dx.doi.org/10.1186/s13075-020-02233-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282084/
https://www.ncbi.nlm.nih.gov/pubmed/32513309
http://dx.doi.org/10.1186/s13075-020-02233-9

Ejemplares similares